Considering MHC-II mediates CD4+ T-cell epitope-initiated immune responses, we hypothesized that combining PCSK9 inhibitors with long peptide vaccines may achieve synergistic anti-tumor effects. The gene discussed is PCSK9; the disease is neoplasm.